JeanMarie Guenot Has Been Redefining Leadership At Amphivena Therapeutics


JeanMarie Guenot is the president and CEO of Amphivena Therapeutics, a company that focuses on the development of innovative bi-functional antibody treatments for hematologic malignancies. She is highly knowledgeable in the pharmaceutical and biotechnology industries. In her 20 years of service, she worked for different companies ranging from public and private, corporate & commercial development, pharmaceutical R&D, venture capital and project & alliance management, to business development.

Jeanmarie’s website highlights how she is highly trained in physical and mechanical chemistry. She pursued legal studies at the University of California, San Francisco. The alumnus of Wharton School at the University of Pennsylvania graduated with an MBA and a doctorate degree. JeanMarie is knowledgeable in the areas of semi-empirical and quantum mechanical methods for molecular dynamics, X-ray and NMR refinement as well as protein structure prediction and drug design. She is also skilled in building and reconstructing companies.

JeanMarie Guenot’s entrepreneurship career started at Atlas Venture where she was in charge of venture capital investments and established life science companies. Her scientific career took off at Hoffman-La Roche, where she served as a principal scientist in Preclinical R&D. Hoffman-La Roche deals with the research and development of treatments for inflammation, metabolic diseases, oncology and autoimmune diseases. Before joining Amphivena Therapeutics, JeanMarie established and managed SKS Ocular.

CrunchBase shows that she also worked as a business advisor for Hoffman-La Roche. Guenot worked for PDL BioPharma as the vice president of Corporate & Business Development. While here, JeanMarie Guenot was responsible for mergers & acquisitions, licensing and alliance management for the company’s R&D and commercial product portfolios. She oversaw and negotiated the strategic collaboration of co-development and co-commercialization of the Biogen Idec-PDL 50:50, a transaction worth $800 million. It involved three candidates of phase 2 cancer and autoimmune disease drug.

In addition, Guenot LLC approved the ophthalmic indication for the oncology drug to Ophthotech Corporation. JeanMarie has a deep background in the management of portfolio, alliance and projects in fields of cardiovascular diseases, oncology, autoimmune diseases, ophthalmic diseases and neurology. This information was originally mentioned on Amphivena’s website as outlined in the following link